0.01%阿托品滴眼液每日两次与一次用于儿童近视控制的两年随机试验结果
Two year randomised trial of twice versus once daily 0.01% atropine for childhood myopia control with real world extension
一项为期两年的随机试验评估了0.01%阿托品滴眼液每日两次与一次用于儿童近视控制的效果。结果显示,每日两次使用阿托品的儿童近视进展较每日一次慢,但在第二年未观察到显著的额外益处。调整后的轴向长度和屈光度变化显示,每日两次使用阿托品的儿童近视进展分别减少了0.132毫米和0.640屈光度。
- Meinan He1 na1,
- Liya Zhang1 na1,
- Chunyu Tang1 na1,
- Wanyuan Bi1,
- Lei Wang1,
- Shuwei Zhang1,
- Ziyu Zhang1,
- Bei Du1 &
- …
- Ruihua Wei1
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
To assess the efficacy of 0.01% atropine eye drops in myopia control with different frequencies (nightly versus twice daily) over a two-year period. Children aged 6 to 13 years with a post-cycloplegic spherical equivalent refraction (SER) between − 0.75 and − 6.00 D were randomly assigned in a 1:1 ratio to receive 0.01% atropine either nightly (QD) or twice daily (BID) during Phase I (the first year). Participants were then given the option to continue into Phase II (the second year), a real-world extension phase without randomization. The primary endpoint was axial length (AL) change over two years; SER change was a key secondary endpoint. A two-year follow-up was completed for 20 and 28 participants in the QD and BID groups, respectively. Over two years, the adjusted increase in AL was 0.523 mm in the QD group and 0.372 mm in the BID group, with an adjusted between-group difference of − 0.132 mm (95% CI − 0.246 to − 0.019; P = 0.023). Adjusted SER progression was − 1.087 D in the QD group and − 0.447 D in the BID group, with an adjusted difference of 0.640 D (95% CI 0.351 to 0.930; P < 0.001). During Phase II, no significant between-group differences were found in AL or SER changes (P = 0.916 and P = 0.247). Twice-daily 0.01% atropine was associated with slower myopia progression over two years, but no significant additional benefit was observed during the second year in this small real-world extension.
Funding
This study was funded by the Tianjin Science and Technology Popularisation project (Grant No. 26KPXCRC00380) and Tianjin Key Medical Discipline Construction Project (TJYXZDXK-3-004A-2). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author information
Author notes
Meinan He, Liya Zhang, and Chunyu Tang have contributed equally to this work.
Authors and Affiliations
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, No.251 Fukang Road, Xiqing District, Tianjin, 300380, China
Meinan He, Liya Zhang, Chunyu Tang, Wanyuan Bi, Lei Wang, Shuwei Zhang, Ziyu Zhang, Bei Du & Ruihua Wei
Authors
- Meinan He
- Liya Zhang
- Chunyu Tang
- Wanyuan Bi
- Lei Wang
- Shuwei Zhang
- Ziyu Zhang
- Bei Du
- Ruihua Wei
Corresponding authors
Correspondence to Bei Du or Ruihua Wei.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
He, M., Zhang, L., Tang, C. et al. Two year randomised trial of twice versus once daily 0.01% atropine for childhood myopia control with real world extension. Sci Rep (2026). https://doi.org/10.1038/s41598-026-75970-7
Received: 10 July 2026
Accepted: 09 October 2026
Published: 02 November 2026
DOI: https://doi.org/10.1038/s41598-026-75970-7
来源:Nature 健康护理主题 · nature.com